Spot on mate. Based on Recce's current pace in trials and clear shift to gain an income stream from eastern countries in order to minimise dilution, I can't see us seeing a RCE drug in westen markets this decade. Any work in this space is more or less for long term, or just to keep the employees (family) busy to justify their exorbitant wages.
Ann: Approval to Start Phase I/II Diabetic Foot Ulcer Study, page-16
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $102.0M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 46.5¢ | 46.0¢ | $19.60K | 42.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 41004 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 38272 | 2 |
View Market Depth
| Last trade - 15.56pm 26/07/2024 (20 minute delay) ? |
| RCE (ASX) Chart |